David A. Siegel Protara Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Protara Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 151,618 shares of TARA stock, worth $817,221. This represents 0.0% of its overall portfolio holdings.
Number of Shares
151,618
Previous 80,518
88.3%
Holding current value
$817,221
Previous $167,000
65.87%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding TARA
# of Institutions
39Shares Held
10.7MCall Options Held
9KPut Options Held
1.8K-
Ra Capital Management, L.P. Boston, MA1.9MShares$10.2 Million0.05% of portfolio
-
Opaleye Management Inc. Boston, MA1.68MShares$9.06 Million0.56% of portfolio
-
Stem Point Capital LP New York, NY943KShares$5.08 Million0.52% of portfolio
-
Woodline Partners LP San Francisco, CA852KShares$4.59 Million0.01% of portfolio
-
Boxer Capital, LLC San Diego, CA812KShares$4.37 Million0.08% of portfolio
About Protara Therapeutics, Inc.
- Ticker TARA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,267,400
- Market Cap $60.7M
- Description
- Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chlorid...